Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles
BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on Aging (NIA)-sponsored study called the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI). This agreement enables the consortium to use MK-6240, Lantheus' clinical-stage F18-labeled Positron Emission Tomography (PET) imaging agent, in its investigation of Alzheimer's disease and related dementias. MK-6240 targets aggregated tau protein in the form of neurofibrillary tangles (NFTs) which are a hallmark of several neurodegenerative diseases, including Alzheimer's disease.
The CLARiTI study will involve all 37 Alzheimer's Disease Research Centers in the United States which will recruit 2,000 subjects and collect their imaging and blood-based biomarker data to generate etiologic profiles for cases of mixed dementia.
"This study is designed to shed light on the complex interplay of multiple pathologies contributing to dementia, ultimately advancing our understanding and treatment of this devastating condition," said Sterling Johnson, PhD, Professor of Medicine, University of Wisconsin School of Medicine and Public Health and the CLARiTI study lead. "We are thrilled to partner with Lantheus to use MK-6240 for tau PET imaging in this important study."
"MK-6240 is poised to play a pivotal role in propelling Alzheimer's diagnosis and treatment research to new heights," said Jean-Claude Provost, MD, Chief Medical Officer, Lantheus. "This agreement aligns with Lantheus' purpose to actively cultivate collaborations that empower researchers worldwide with essential tools to accelerate clinical research and development of therapies. In an era defined by an unprecedented number of Alzheimer's diagnoses, the CLARiTI study represents a significant milestone in Alzheimer's research, with the potential to change the trajectory of this degenerative disease."
About the CLARiTI Study
Clarity in Alzheimer's Disease and Related Dementias Research Through Imaging (CLARiTI) is a multi-site imaging observational study that will be conducted at all 37 Alzheimer's Disease Research Centers (ADRCs) in the United States. The study will collect data about the presence, absence or change in characteristic disease biomarkers in people who have various types of dementia or are at risk of developing it. CLARiTI is a five-year study that will enroll 2,000 subjects across the U.S. Data generated from CLARiTI will be made available to the scientific community through the National Alzheimer's Coordinating Center, and biological samples will be analyzed and made available through the National Centralized Repository for Alzheimer's Disease and Related Dementias.
Please visit https://naccdata.org/nacc-collaborations/clariti for more information about the study.
About Alzheimer's Disease and Dementia
Alzheimer's disease is a progressive degenerative brain disease and the most common form of dementia. Dementia is the loss of cognitive functioning and behavioral abilities to such an extent that it interferes with a person's daily life and activities. Dementia is not a specific disease; it describes a group of symptoms that often has a mixture of etiologies. It is estimated that 6.7 million Americans age 65 and older are currently living with Alzheimer's dementia. As the population ages, it is projected that by 2050, this number may grow to 12.7 million.1
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by their use of terms such as "designed," "poised," "potential," "will" and other similar terms. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause the Company's actual results to materially differ from those described in the forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission (including those described in the Risk Factors section in the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q).
1Alzheimer's Association. 2023 Alzheimer's Disease Facts and Figures. Alzheimer's Dement 2023;19(4). DOI 10.1002/alz.13016.
Vice President, Investor Relations
Senior Director, External Communications